Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Curr Opin Allergy Clin Immunol. 2021 Apr 1;21(2):202–215. doi: 10.1097/ACI.0000000000000725

Table 1: Summary of results from mouse models of OA.

that interrogate lung function in OA cohorts compared to healthy control, asthma-alone and obesity-alone cohorts. Up arrows (↑) indicate enriched populations, down arrows (↓) indicate less prevalent populations, sideways arrows (→) indicate no significant difference measured and double hyphens (--) indicate no data was reported for the given variable. Each color-coded row represents the pairwise comparison specified in the table legend (dark gray= OA vs healthy control; white= OA vs asthma alone, light gray= OA vs obesity alone). Asthma: A= Allergen used to induce asthma, B= Immunization protocol, C= Challenge protocol. Within the immunization protocol (Asthma, B) and challenge protocol (Asthma, C) description, s.c. = subcutaneous, i.n. = intra-nasal, i.t.= intra-tracheal, (w/v) = weight per volume. Diet Induced obesity: D= High-fat diet (HFD) vendor, E= Catalog number of HFD, F= Percent of energy derived from HFD, G=Number of weeks on HFD. Pulmonary Function: AHR= Airway Hyperresponsiveness, AR= Airway Remodeling. Immune Response: Eos= Eosinophils, Neu= Neutrophils, MΦ= Macrophage.

Publication Mouse Model Pulmonary Function Immune Response Adipokines
First Author Year Sex Strain Asthma Diet Induced Obesity AHR AR T cells Cytokines Eos Neu Leptin Adiponectin
Lee [89] 2019 F C57BL/6 A) OVA
B) 25μg s.c. (2x)
C) 20μg/50μl i.n. (4x)
D) Harlan Laboratories
E) D12492
F) 60%
G) 12
-- Lung: ↑ IL-17
BALF: ↑ IL-4/5/13/17; ↓IFNγ
Serum: ↑ IL-17
Lung: ↑1
BALF: ↑
Lung: ↑1
BALF: ↑
BALF: ↑ BALF: ↑
Serum: ↑
BALF: →
Serum: →
-- Lung: → IL-17
BALF: →IL-4/13/17; ↓IFNγ; ↑ IL-5
Serum: ↑ IL-17
Lung: →1
BALF: →
Lung: →1
BALF: →
BALF: → BALF: ↑
Serum: ↑
BALF: →
Serum: →
-- -- -- -- -- -- -- -- --
Schröder [90] 2019 F C57BL/6JRj A) OVA
B) 150μg/1mg i.p. (2x)
C) 1.5% i.t.(4x)
D) Ssniff EF R/M
E) TD88137
F) 42%
G) 12
Lung: ↑ CD4+
BALF: ↑ T cells
BALF: ↑ BALF: ↑ BALF: → -- --
Lung: → CD4+
BALF: ↓ T cells
BALF: → BALF: ↓ BALF: → -- --
Lung: ↑ CD4+
BALF: → T cells
BALF: ↑ BALF: ↑ BALF: → -- --
Zeng [91] 2019 M C57BL/6 A) OVA
B) 10μg i.p. (2x)
C) 1 mg/mL aerosol (30 min daily × 7d)
D) MediScience Ltd.
E) MD12032
F) 45%
G) 16
Lung: ↑ Th17 Lung1: ↑ IL17A, RORγt
Serum: ↑IL-1β/6/17A
-- -- -- -- --
Lung: → Th17 Lung1: → IL17A, RORγt
Serum: ↑IL-1β/6/17A
-- -- -- -- --
Lung: → Th17 Lung1: → IL17A, RORγt
Serum: ↑IL-1β/6/17A
-- -- -- -- --
*Chong [92] 2018 M/F C57BL/6J A) OVA
B) 0.01% OVA i.p.
C) 1% OVA aerosol (30 min daily × 8d)
D) MediScience Ltd.
E) MD12032
F) 45%
G) 12
-- -- BALF: ↑ BALF: ↑ -- -- --
-- -- -- -- -- -- --
-- -- BALF: ↑ BALF: ↓ -- -- --
Liang [93] 2018 F C57BL/6 A) OVA
B) 25μg i.p. (2x)
C) 20μg/50μL i.n. (3x)
D) Harlan Laboratories
E) D12492
F) 60%
G) 12
-- BALF: ↑ IL-4/5/13/17 BALF: ↑ BALF: → BALF: ↑ Serum: ↑ Serum: ↓
-- BALF: ↑ IL-4/5/17; → IL-13 BALF: ↑ BALF: → BALF: ↑ Serum: ↑ Serum: ↓
-- BALF: ↑ IL-4/5/13/17 BALF: ↑ BALF: → BALF: ↑ Serum: ↑ Serum: ↑
Zeng [94] 2018 M C57BL/6 A) OVA
B) 10μg i.p. (2x)
C) 1 mg/mL aerosol (30 min daily × 7d)
D) MediScience Ltd.
E) MD12032
F) 45%
G) 16
Spleen: ↑Th17 Lung1: ↑IL-17A
Serum: ↑IL-17
-- -- -- -- --
Spleen: ↑Th17 Lung1: ↑IL-17A
Serum: ↑IL-17
-- -- -- -- --
Spleen: ↑Th17 Lung1: ↑IL-17A
Serum: ↑IL-17
-- -- -- -- --
*Everaere [101] 2016 -- C57BL/6J A) HDM
B) 5 IR i.n. (1x)
C) 5 IR i.n. (5x)
D) Research Diet Inc.
E) D12492
F) 60%
G) 12
Lung: ↑ CD4+, IL13+CD4+, IL-17A+CD4+ Lung2: ↑IL-1β/4/13/17A/23/33
VAT2: → IL-1β/17A, IFNγ; ↓IL-5/33
BALF: ↑ BALF: → BALF: → -- --
Lung: ↑ CD4+, IL13+CD4+, IL-17A+CD4+ Lung2: ↑IL-1β/4/13/17A/23/33
VAT2: → IL-1β/17A, IFNγ; ↓IL-5/33
BALF: ↑ BALF: → BALF: → -- --
Lung: → CD4+, IL13+CD4+, IL-17A+CD4+ Lung2: ↑IL-4/13/17A/33; → IL-1β/23
VAT2: → IL-1β/17A, IFNγ; ↓IL-5/33
BALF: ↑ BALF: → BALF: → -- --
Chen [95] 2015 -- BALB/c A) OVA
B) 25μg i.p. (3x)
C) 6% (w/v) aerosol
(daily × duration of diet > 12 weeks)
D) Research Diet Inc.
E) D12451
F) 45%
G) 12
-- Serum: ↑IL-4; ↓IFNg Lung: ↑ -- -- -- --
-- Serum: →IL-4; ↓IFNg Lung: ↑ -- -- -- --
-- Serum: ↓IL-4; IFNg Lung: ↑ -- -- -- --
Kim [96] 2015 F C57BL/6 A) OVA
B) 100μg i.p. (2x)
C) 10μg i.n. (3x)
D) Research Diet Inc.
E) D12492
F) 60%
G) 16
-- BALF: ↑ TNFα
Serum: ↑ TNFα
BALF: ↑ BALF: ↑ -- Lung: →
Serum: →
Lung: →
Serum: →
-- Lung: ↑ TNFα
BALF: ↑ TNFα
Serum: ↑ TNFα
BALF: → BALF: → -- -- --
-- BALF: ↑ TNFα
Serum: ↑ TNFα
BALF: ↑ BALF: ↑ -- -- --
Jung [98] 2013 F C57BL/6J A) OVA
B) 25μg s.c. (5x)
C) 20μg/50μL i.n. days 27, 29, 31 and then twice a week until week 18
D) Feedlab
E) --
F) 45%
G) 16
-- Lung2: ↑ VEGF, TNFα, TGFβ
BALF: ↑ VEGF, TNFα, TGFβ
BALF: ↑ BALF: ↑ BALF: ↑ Lung: ↑ Lung: ↓
-- Lung2: → VEGF, TGFβ; ↑ TNFα
BALF: ↑ TNFα; → VEGF; ↓ TGFβ
BALF: ↑ BALF: → BALF: → Lung: ↑ Lung: ↓
-- Lung2: → VEGF, TGFβ, ↑ TNFα
BALF: ↑TNFα; →VEGF; ↓TGFβ
BALF: ↑ BALF: ↑ BALF: ↑ Lung: ↓ Lung: ↑
Ryu [99] 2013 F C57BL/6J A) OVA
B) 25μg s.c. (5x)
C) 20μg/50μL i.n. days 27, 29, 31 and then twice a week until week 18
D) Feedlab
E) --
F) 45%
G) 16
-- -- Lung2: ↑ VEGF, TNFα, TGFβ
BALF: ↑ VEGF, TGFβ
BALF: ↑ BALF: ↑ BALF: ↑ Lung2: ↑ Lung2: →
-- -- Lung2: ↑ VEGF, TNFα, TGFβ
BALF: ↑ TGFβ; → VEGF
BALF: → BALF: → BALF: → Lung2: → Lung2: →
-- -- Lung2: ↑ TNFα, TGFβ; ↓ VEGF
BALF: ↓TGFβ, VEGF
BALF: ↑ BALF: → BALF: ↑ Lung2: → Lung2: →
Ge [97] 2013 M C57BL/6J A) CRA
B) 10μg s.c. + 10μg i.p (1x), 1μg s.c. (1x) (2x)
C) 1μg i.n. (1x) then 4μg i.n. (1x)
D) Bio-Serv
E) F3282
E) 60%
F) 16
-- Lung: ↑ IL-5, → IFNγ, IL-2/4/13, ↓ TNFα, Lung: ↑
BALF: ↓
BALF: ↓ BALF: ↑ -- --
-- Lung: → IL-4; ↓ IFNγ, TNFα, IL-2/5/13 Lung: ↓
BALF: ↓
BALF: ↓ BALF: ↑ -- --
-- Lung: ↑ IL-5; → IFNγ, TNFα, IL-2/4/13 Lung: ↑
BALF: ↑
BALF: ↑ BALF: ↑ -- --
Table Legend
Obese Asthma vs Healthy Control
Obese Asthma vs Asthma Alone
Obese Asthma vs Obesity Alone